Due to shared modes of transmission, hepatitis C virus (HCV) infection is common in persons living with human immunodeficiency virus (HIV) infection.
1,2 Increasingly, liver disease due to chronic HCV is a major cause of morbidity and mortality in this population and represents a leading cause of death in many settings. 3, 4 Current guidelines recommend that patients with HIV/HCV coinfection undergo HCV treatment with the combination of peginterferon (PegIFN) and ribavirin (RBV). 5, 6 Indeed, on the basis of large randomized controlled trials, the combination of PegIFN α-2a and RBV is approved for the treatment of hepatitis C in HIV-infected patients in the United States and other countries. [7] [8] [9] More recently, data from several large prospective longitudinal HIV cohort studies have provided strong evidence that HCV treatment that results in sustained virologic response or cure of chronic HCV infection is associated with decreased risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death.
10,11
Despite the high burden of HCV disease and the availability of antiviral treatment that has been shown to improve clinical outcomes, few persons with HIV/HCV coinfection have been treated with PegIFN/RBV and even fewer have achieved sustained virological response. [12] [13] [14] For example, less than 10% of HIV/HCV coinfected patients receiving care in the United States Veterans Affairs system have received PegIFN based HCV treatment; in the Johns Hopkins HIV clinic, only 15% of patients treated with PegIFN/RBV achieved a sustained virologic response. 10, 15 The reasons for the limited effectiveness of PegIFN based HCV treatment in this population include (1) high prevalence of medical (e.g., anemia, acquired immunodeficiency syndrome [AIDS] ) and psychiatric (e.g., depression) comorbid conditions in patients with HIV/HCV coinfection that may prevent the safe administration of PegIFN; (2) higher levels of HCV RNA in the blood in patients with HIV infection compared with those without HIV infection; (3) blunted antiviral response to PegIFN in HIV/HCV coinfected patients relative to HCV monoinfected patients; (4) relatively high incidence of treatment related-adverse effects that impair the ability of HIV/HCV coinfected patients to adhere to prolonged course of IFN and limit the willingness
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In the era of effective treatment for human immunodeficiency virus (HIV) infection, coinfection with hepatitis C virus (HCV) is an important cause of morbidity and mortality. Similar to other observations made in other HCV-infected patient populations, treatment of chronic HCV infection that results in sustained virologic response or eradication of the hepatitis infection has been strongly associated with decreased likelihood of end-stage liver disease and/or hepatocellular carcinoma and improved overall survival in HIV-infected patients. However, the effectiveness of HCV treatment has been limited due to frequent contraindications to interferon-α (INFα) and prior to the advent of HCV direct acting antivirals, relatively low rates of sustained virologic response. Since 2011, the efficacy of HCV treatment in coinfected patients has improved substantially with the addition of HCV direct-acting antivirals to INFα-based regimens. Based on these observations, there is mounting optimism that INFα-free, oral HCV treatments will further improve efficacy, and more importantly, increase access to treatment for many coinfected patients.
of coinfected patients and their HIV care providers to initiate HCV treatment with this drug. [16] [17] [18] Accordingly, more effective and better tolerated HCV treatment regimens represent an important unmet medical need for patients with HIV/HCV coinfection. The expectation is that this urgent medical need will be addressed by many of the multitude of novel HCV antivirals that are in late-stage clinical development. In 2011, the first of these direct-acting antivirals (DAAs), telaprevir and boceprevir, were approved for the treatment of chronic HCV genotype 1 infection in combination with PegIFN/RBV. 19, 20 
27
While the role of INFα remains under investigation in the effort to cure chronic HIV infection, its utility in the treatment of chronic HCV infection has been limited by multiple factors including (1) Adverse effects that restrict patient eligibility for its use in all patient populations, and (2) impaired antiviral response in patients with HIV/HCV coinfection compared with those with HCV alone. First, at doses used to treat hepatitis C infection, INFα is associated with fatigue, depression, and bone marrow suppression, leading to lymphopenia and neutropenia as well as a myriad of other side effects.
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Not unexpectedly, many patients with HIV/HCV coinfection have medical and/or psychiatric contraindications to the use of INFα. For example, in an examination of the United States Veterans Affairs Clinical Case Registry, only 35% of HCVinfected patients were deemed eligible for IFN-based treatment and only 7% of HIV/HCV coinfected patients had received treatment.
14,15 Second, INFα therapy appears to be less effective for the treatment of HCV in patients with HIV infection compared with those with HCV alone. In studies of HCV kinetics with INFα therapy, Sherman and colleagues found that after 48 weeks of treatment HCV RNA level was undetectable at 72 weeks in 25% and 40% of HIV/HCV coinfected and HCV monoinfected patients, respectively.
29
The researchers reported that HIV infection was associated with prolonged viral clearance and that the basis of this delayed HCV clearance was due primarily to higher levels of HCV RNA at baseline in coinfected patients compared with monoinfected patients. The observation that HIV-infected patients have higher levels of HCV RNA than HIV-uninfected patients is well established. Indeed, as early as 1994, Eyster and coworkers observed that HCV RNA levels increased in men with hemophilia following HIV seroconversion and multiple studies of patients with chronic HCV infection have demonstrated that those with HIV coinfection have higher levels of hepatitis C viremia compared with those without HIV. Interferon-Containing and Interferon-Free HCV Therapy for HIV-Infected Patients Sulkowski 73
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patients with HCV RNA levels greater than 800,000 copies/mL prior to treatment had a sustained virologic response rate of 18% (23 of 130 patients); in contrast, those with HCV RNA levels less than 800,000 copies/mL prior to treatment had a sustained virologic response rate of 61% (28 of 46 patients).
7
By comparison, in the study by Hadziyannis and colleagues, HCV monoinfected patients were treated with the same regimen, PegIFN α-2a and fixed-dose RBV (800 mg/d) for 48 weeks. Monoinfected patients with HCV RNA levels greater than 800,000 copies/mL prior to treatment had a sustained virologic response rate of 36%; in contrast, those with HCV RNA levels less than 800,000 copies/mL prior to treatment had a sustained virologic response rate of 55%. 34 In this crossstudy comparison of patients with high HCV RNA levels, the efficacy of PegIFN-based therapy was markedly lower in patients with HIV/HCV coinfection (18%) compared with HCV monoinfection (36%) (►Fig. 1). response occurred in 75% (271 of 365 patients). 19 Similarly, for the regimen of boceprevir in combination with PegIFN and RBV, the sustained virologic response rate in patients with HCV genotype 1/HIV coinfection was 63% (40 of 64 patients).
In the study of boceprevir plus PegIFN and RBV by Poordad and colleagues, the corresponding sustained virologic response rate in persons with HCV genotype 1 infection alone was 68% (213 of the 311 patients).
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The combination of simeprevir plus PegIFN and RBV has also been investigated in patients with and without HIV infection. In a study of 106 patients with HIV and HCV genotype 1 coinfection treated with this regimen, the overall sustained virologic response rate was 74% and, among those who had not undergone prior HCV treatment (naïve), the efficacy was 79%. 37 In two studies of HIV uninfected persons regimen of sofosbuvir plus PegIFN and RBV was also studied by Lawitz and colleagues in HIV-uninfected patients in the NEUTRINO study; in patients with HCV genotype 1 infection, the sustained virologic response rate was 89%.
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Although the studies of a single DAA plus PegIFN and RBV are relatively small and do not directly compare the efficacy in patients with or without HIV coinfection, the HCV treatment regimens have achieved similar efficacy in both patient populations. Indeed, the regulatory approvals in the United States and Europe of the nucleotide analogue NS5B polymerase inhibitor, sofosbuvir, provide labeling for the use of this agent in patients with HIV coinfection. Similarly, the regulatory approval in the United States (pending in Europe) of the HCV NS3/4A protease inhibitor, simeprevir, provides specific recommendations for drug interactions of this drug and commonly prescribed antiretroviral agents. Further, these data provide strong support for the hypothesis that oral, DAAs will have similar anti-HCV efficacy in the setting HIV infection and that the ability of the host to eradicate chronic HCV infection during antiviral treatment is not adversely impacted by the direct or indirect effects of HIV infection. Based on these promising results with INFα, the removal of INFα from combination HCV treatment regimens is expected to increase patient eligibility for treatment as well as result in greater efficacy in the setting of high levels of HCV RNA.
Encouraging Preliminary Data for Interferon-Free, Oral Direct Acting Antiviral Therapy in HIV-Infected Patients
Adequate tests of the hypothesis that efficacy will be similar in patients with and without HIV infection will require large, adequately powered studies in both patient populations; at this time, many such studies have been initiated (►Table 2). To date, the PHOTON-1 study is the only IFN-free study to report sustained virologic response data. 41 In this study, sofosbuvir and weight-based RBV were administered to 114 treatment-naïve patients with HCV genotype 1 for 24 weeks and 68 treatment-naive patients with HCV genotype 2 or 3 for 12 weeks. Among treatment-naïve patients with HIV infection, the sustained virologic response rates were 76% for patients with genotype 1 infection, 88% for patients with genotype 2 infection, and 67% for patients with genotype 3 infection. This same regimen, sofosbuvir plus weight based RBV for 12 or 24 weeks, has also been studied in HIV-uninfected patients in two different studies. 21, 42 For HIV-uninfected patients with HCV genotype 1 infection in the SPARE study, Osinusi and coworkers reported that 68% of patients treated with sofosbuvir and weight-based RBV for 24 weeks achieved sustained virologic response. 42 Similarly, in the FISSION study, Lawitz and colleagues reported that sustained virologic response occurred in 97% of patients with genotype 2 and in 56% of those with genotype 3 treated with sofosbuvir and weightbased RBV for 12 weeks. Interesting, the C-WORTHY study is enrolling both patient populations-HIV-infected and uninfected patients-in the same HCV study protocol. This study design underscores the emerging recognition that HIV-infected patients may not be unique in terms of the effectiveness of oral, IFN-free DAA regimens.
Conclusions
Multiple IFN-free clinical trials are underway in persons with HIV/HCV coinfection; these studies are anticipated to demonstrate that oral, DAAs for HCV have similar efficacy in patients with and without HIV coinfection, lending additional support to the hypothesis that HIV coinfection does not adversely impact the effectiveness of these highly active HCV treatments. If, as expected, these studies yield high rates of sustained virologic response with acceptable safety and tolerability profiles, the remaining challenge to the management of HCV infection in persons with HIV coinfection will be the need to carefully consider the potential drug interactions between the patient's antiretroviral drug regimen and the HCV DAA drug regimen. [43] [44] [45] For some patient's and some drug regimens, this may represent the combination of as many as 10 unique antiviral drugs each with a different mechanism of action to inhibit HIV or HCV or to block antiviral drug metabolism through inhibition of the patient's cytochrome P450 pathways with pharmacologic enhancers, such as ritonavir or cobicistat.
46,47
Full understanding of the potential for drug interactions between highly active drug regimens for the treatment of HCV and HIV is required before these regimens can be safely combined for routine use in clinical practice. Indeed, due to complex drug interactions with some antiviral agents, the expectation is that not all antiretroviral regimens will be able to be safely combined with all HCV DAA regimens; as such, clinicians who treat patients with HIV/HCV coinfection will need to carefully select the most appropriate HIV and HCV treatment regimens for each patient. However, it is important to recognize that HCV treatment is finite, leading to cure of the chronic HCV infection. 48, 49 Further, the anticipated duration of HCV treatment with oral DAAs will be only 12 or 24 weeks for most HIV/HCV coinfected patients. Accordingly, complex drug interactions will not be an insurmountable barrier to HCV eradication for patients with HIV coinfection. Of course, the availability of safe and effective oral HCV DAAs is merely the first step toward controlling HCV disease in HIV-infected patients; comprehensive strategies to effectively and economically deliver these HCV treatments to the nearly 5 million patients with HIV/HCV coinfection worldwide will be critical to effectively address this curable, life-threatening infection. 
